Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Peter J. Allen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7912-9197; OpenAlex author ID A5036762729. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 1, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
119
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 trial · 2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 18

  1. Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients With Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/op-25-00548↗
  2. Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer. Co-author DOI 10.1200/po-25-00115↗
  3. Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients. Co-author DOI 10.1245/s10434-025-18232-6↗
  4. Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples. Co-author DOI 10.1126/sciadv.adt0029↗
  5. Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Co-author DOI 10.1186/s12967-025-07381-7↗
  6. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  7. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-023-14751-2↗
  8. Revisiting the intrinsic mycobiome in pancreatic cancer. Last author DOI 10.1038/s41586-023-06292-1↗
  9. Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Ass… Co-author DOI 10.1097/sla.0000000000005313↗
  10. Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemotherapy. Co-author DOI 10.1245/s10434-023-13318-5↗
  11. Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Co-author DOI 10.3389/fimmu.2023.1116034↗
  12. Heterogeneity of glycan biomarker clusters as an indicator of recurrence in pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1135405↗
  13. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adeno… Co-author DOI 10.1177/0003134821989050↗
  14. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Co-author DOI 10.1007/s00261-020-02726-w↗
  15. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Co-author DOI 10.1158/1078-0432.ccr-20-2475↗
  16. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Co-author DOI 10.1158/1940-6207.capr-18-0272↗
  17. Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000590↗
  18. Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. First author DOI 10.1097/mpa.0000000000000705↗

Trials 1

  1. The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) Principal investigator NCT04207944↗

Closest collaborators

The 25 strongest of 119 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel P. Nussbaum · 5 shared papers, 2023–2026 · strength 1.31
  2. Austin M. Eckhoff · 4 shared papers, 2023–2024 · strength 0.85
  3. Dan German Blazer · 3 shared papers, 2023–2026 · strength 0.69
  4. Michael E. Lidsky · 3 shared papers, 2023–2026 · strength 0.69
  5. Elishama N. Kanu · 3 shared papers, 2023–2026 · strength 0.68
  6. Kevin C. Soares · 4 shared papers, 2022–2025 · strength 0.61
  7. Chanjuan Shi · 3 shared papers, 2023–2025 · strength 0.54
  8. ChongFeng Gao · 3 shared papers, 2021–2025 · strength 0.51
  9. Brian B. Haab · 3 shared papers, 2021–2025 · strength 0.51
  10. Vinod P. Balachandran · 3 shared papers, 2021–2025 · strength 0.43
  11. Michael Ian D'Angelica · 3 shared papers, 2021–2025 · strength 0.43
  12. Jeffrey A. Drebin · 3 shared papers, 2021–2025 · strength 0.43
  13. William R. Jarnagin · 3 shared papers, 2021–2025 · strength 0.43
  14. Sabino Zani · 2 shared papers, 2023–2025 · strength 0.39
  15. Randall E. Brand · 3 shared papers, 2016–2025 · strength 0.35
  16. Ryne C. Ramaker · 1 shared paper, 2026 · strength 0.33
  17. John H. Strickler · 1 shared paper, 2026 · strength 0.33
  18. Ethan S. Agritelley · 1 shared paper, 2026 · strength 0.33
  19. Alice Chia-Chi Wei · 2 shared papers, 2022–2025 · strength 0.33
  20. Luke Wisniewski · 2 shared papers, 2021–2023 · strength 0.31
  21. Ben Staal · 2 shared papers, 2021–2025 · strength 0.30
  22. Aatur Dilip Singhi · 2 shared papers, 2021–2025 · strength 0.30
  23. Ying Huang · 2 shared papers, 2021–2025 · strength 0.30
  24. Sabran J. Masoud · 1 shared paper, 2026 · strength 0.30
  25. Allison N. Martin · 1 shared paper, 2026 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.